The Food and Drug Administration has authorized a monoclonal antibody cocktail as a measure to prevent infection in some groups of people who were exposed to the CCP virus, the pathogen that causes COVID-19.
The FDA on Friday announced that it had revised its emergency use authorization for REGEN-COV, a treatment consisting of jointly administered casirivimab and imdevimab, expanding its use beyond just the treatment of patients who test positive for the virus.
The antibody treatment is only authorized for use in people who have been exposed to the CCP virus, not as a pre-exposure preventive measure, the FDA said.
"Prophylaxis with REGEN-COV is not a substitute for vaccination against COVID-19," the FDA noted, while urging people to get the shot.
The trial found an 81 percent reduction in confirmed symptomatic COVID-19 cases in people testing negative at the start of the study and who had household contact with people who were infected with the virus.
Dr. Myron Cohen, a researcher at the University of North Carolina at Chapel Hill and one of the investigators behind the study of COVID-19 antibodies, told NBC that the REGEN-COV drug cocktail works by overwhelming the infection while it is still in its early stages.
"It's a race between your ability to make an antibody to protect your lungs and the rest of your body and the virus," Cohen told the outlet.
It's becoming increasingly difficult to discern fact from fiction, and unfortunately the media has a strong bias. They spin stories to make conservatives look bad and will go to great lengths to avoid reporting on the good that comes from conservative policies. There are a few shining lights in the media landscape-brave conservative outlets that report the truth and offer a different perspective. We must support conservative outlets like this one and ensure that our voices are heard.
Wednesday, August 4, 2021
FDA Authorizes Antibody Cocktail as COVID-19 Prevention Treatment
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment